Ozempic, Novo Nordisk and European Medicines Agency
Novo Nordisk's Ozempic set to include kidney treatment label in EU
Novo Nordisk announced on Thursday that a key European Medicines Agency committee has backed a label update for weight-loss drug Ozempic to include the reduction of kidney disease risk. The decision was based on findings of a trial,
Novo Nordisk's Ozempic Gets CHMP's Positive Opinion To Include Kidney Disease Label Update
Thursday announced that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has supported label update for weight-loss drug Ozempic to include kidney disease risk reduction.
COPENHAGEN (Reuters) - Denmark has again raised its outlook for economic growth, fuelled by the expansion of the country's ...
Denmarks economic prospects are surging, with the government revising GDP growth forecasts upwards for 2024 and 2025, largely ...
In recent months Novo Nordisk has invested several billions of dollars to boost its manufacturing capacity—including its ...
Denmark’s central bank followed its European counterpart with a quarter-point interest-rate cut to defend the krone’s peg to ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
TD Cowen analyst Michael Nedelcovych maintained a Buy rating on Novo Nordisk (NVO – Research Report) today and set a price target of $155.00.
Novo Nordisk keeps manufacturing expansion spree rolling with plans for $400M quality hub in Denmark
Amid a multi-year, multibillion-dollar spending spree to scale its global manufacturing capacity, Novo Nordisk is laying down ...
On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No ...
Danish diabetes and obesity giant Novo Nordisk has announced plans to invest 2.9 billion Danish kroner ($410 million) to ...
Novo Nordisk's team in India has been pushing the Danish drugmaker's global leadership for an earlier launch of its popular ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback